Clinical Trial Update: Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population. [Phase 2]

View source ↗

Summary

Phase 2 trial of intralesional cidofovir for recalcitrant warts in immunosuppressed pediatric patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Verruca Vulgaris

Drugs mentioned

• Cidofovir (intralesional) (cidofovir)

Snippet

Sponsor: University of Minnesota | Conditions: Warts | Phase 2 | Status: WITHDRAWN